Table 2.

Univariate analysis of growth factor (GF) usage at any cycle^* and first cycle febrile neutropenia^**

Factor	Level	Number of Patients	Growth Factor		Febrile Neutropenia
			Use at any cycle N (%)	p-value	Observed in first cycle of therapy N (%)	p-value
Induction treatment	R-CHOP	250	83(33)	0.99	40(16)	0.08
	CHOP	270	90(33)		60(22)
Age (yrs)	<65	130	29(22)	0.003	13(10)	0.002
	≥65	390	144(37)		87(22)
Gender	Male	262	79(30)	0.14	42(16)	0.07
	Female	258	94(36)		58(23)
ECOG performance status	0–1	447	151(34)	0.6	78(17)	0.02
	2–3	73	22(30)		22(30)
Hemoglobin (g/dl)	<12	211	92(44)	<0.0001	58(27)	0.0001
	≥12	309	81(26)		42(14)
Lactic dehydrogenase	Normal	217	64(29)	0.13	31(14)	0.02
	Elevated	302	109(36)		69(23)
Marrow involvement	No	422	137(32)	0.48	78(18)	0.39
	Yes	98	36(37)		22(22)
Bulky disease (≥10 cm)	No	408	140(34)	0.37	78(19)	0.89
	Yes	112	33 (29)		22(20)
Ann Arbor stage	I–II	139	44(32)	0.67	29(21)	0.62
	III–IV	381	129(34)		71(19)
International Prognostic***	Low/LI	305	66(31)	0.34	31(14)	0.02
Index (IPI) group	HI/High	214	107(35)		69(23)
Age-adjusted***	Low/LI	257	78(30)	0.16	42(16)	0.10
IPI group	HI/High	262	95(36)		58(22)

^*GF use is defined as yes if GF was used either to prevent dose reduction/dose delay, or as prophylaxis in patients with a prior FN hospitalization, and was given within Days 1–6 of the treatment cycle

^**Fisher’s exact p-value is reported

^***LI=Low intermediate